Investigational drug · Phase 2
TU-100
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Delay in GI Recovery/Postoperative Ileus (POI).
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
10
Any phase or sponsor naming "TU-100"
First trial start
2026
Dec 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TU-100", any sponsor or status.
- Phase 210
Conditions studied
As listed on its trial records.
- Delay in GI Recovery/Postoperative Ileus (POI)
Largest trials
Live from ClinicalTrials.gov: studies naming "TU-100" as an intervention, largest first.
- Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery After Surgery in Subjects Undergoing Bowel ResectionPivotal-lookingCompleted
Tsumura USAIndustry
NCT04742907 · 402 participants · Start Jul 29, 2021 · Primary completion Mar 25, 2024
Drug: TU-100; Placebo · For: Enhanced Recovery After Surgery
Sites: Florence, Alabama; Gilbert, Arizona; Little Rock, Arkansas · 36 sites in all
- TU-100 for Accelerating GI Recovery After Major Abdominopelvic Surgery (RC & CAWR)Pivotal-lookingNot yet recruiting
Tsumura USAIndustry
NCT07765589 · 240 participants (planned) · Start Dec 2026 · Primary completion Jun 2028
Drug: TU-100; Placebo · For: Delay in GI Recovery/Postoperative Ileus (POI)
- A Safety and Efficacy Study of Daikenchuto (TU-100) to Relieve Abdominal Bloating in Female Subjects With Irritable Bowel SyndromePivotal-lookingCompleted
Tsumura USAIndustry
NCT02074579 · 101 participants · Start Jul 2014 · Primary completion Apr 2016
Drug: TU-100; Placebo · For: Irritable Bowel Syndrome in Females
Sites: Los Angeles, California
Tsumura USAIndustry
NCT01388933 · 79 participants · Start Sep 2011 · Primary completion Sep 2013
Drug: TU-100; Matching Placebo · For: Crohn's Disease
Sites: Little Rock, Arkansas; Corona, California; San Carlos, California · 27 sites in all
Tsumura USAIndustry
NCT02232893 · 69 participants · Start Sep 2014 · Primary completion May 2017
Drug: Daikenchuto (TU-100); Placebo · For: Postoperative Ileus
Sites: Los Angeles, California; Aurora, Colorado; Weston, Florida · 13 sites in all
Tsumura USAIndustry
NCT00871325 · 60 participants · Start Jun 2009 · Primary completion Dec 2009
Drug: Daikenchuto (TU-100); Daikenchuto (TU-100) and 1 more · For: Postoperative Ileus
Sites: Rochester, Minnesota
Tsumura USAIndustry
NCT01348152 · 50 participants · Start Sep 2011 · Primary completion Jul 2013
Drug: DAIKENCHUTO (TU-100); Placebo · For: Functional Constipation
Sites: Minneapolis, Minnesota
Tsumura USAIndustry
NCT01139216 · 45 participants · Start Aug 2010 · Primary completion Nov 2012
Drug: Daikenchuto (TU-100); Daikenchuto (TU-100) and 1 more · For: Functional Constipation; Gastric Emptying; Whole Gut Transit and 4 more
Sites: Rochester, Minnesota
Tsumura USAIndustry
NCT01890837 · 40 participants · Start Aug 2013 · Primary completion Mar 2015
Drug: Daikenchuto (TU-100); Placebo · For: Irritable Bowel Syndrome; Digestive System Diseases; Gastrointestinal Diseases and 2 more
Sites: Rochester, Minnesota
Tsumura USAIndustry
NCT00266461 · 24 participants · Start Dec 2005 · Primary completion Jan 2008
Drug: Daikenchuto Extract Granules (TU-100) · For: Postoperative Ileus
Sites: St Louis, Missouri
Newest research
PubMed records naming it or its code names, newest first.
- Effect of TU-100 on Colorectal Liver Metastasis in Mouse Model of Metabolic Dysfunction-Associated Steatohepatitis.
Yamada S, Morine Y, Ikemoto T, et al. · J Surg Res 2026
- Evaluation of TU-100 (Daikenchuto), a Traditional Japanese Kampo Medicine, as an Adjunct to Enhanced Recovery After Surgery, for Acceleration of Gastrointestinal Recovery After Bowel Resection: Results of a Proof-of-Concept, Phase 2, Randomized, Double-Blinded, Placebo-Controlled Trial.
Nedeljkovic SS, Silinsky JD, Nagle D, et al. · Dis Colon Rectum 2026
- Corrigendum to "Intestinal, portal, and peripheral profiles of daikenchuto (TU-100)'s active ingredients after oral administration".
· Pharmacol Res Perspect 2024
- Impact of Daikenchuto (TU-100) on the early postoperative period in duodenal-jejunal bypass.
Kashihara H, Okikawa S, Morine Y, et al. · J Med Invest 2024
- TU-100 Antagonizes the M2 Polarization Phenotype of Macrophages in the Tumor Microenvironment by Suppressing the TLR4/NF-B/STAT3 Axis.
Chen S, Morine Y, Saito YU, et al. · Anticancer Res 2023
- Organocatalyzed Ring-Opening Polymerization of (S)-3-Benzylmorpholine-2,5-Dione.
Göppert NE, Dirauf M, Liebing P, et al. · Macromol Rapid Commun 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.